Laborjournal<p>In München und Singapur werkelt das <a href="https://mstdn.science/tags/Startup" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Startup</span></a> Eximmium an neuen Antikörpern gegen <a href="https://mstdn.science/tags/Krebs" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Krebs</span></a> – und macht sich dabei ein ungeklärtes Phänomen von Krebszellen zunutze. <span class="h-card" translate="no"><a href="https://mastodon.social/@InsertCaffeine" class="u-url mention" rel="nofollow noopener noreferrer" target="_blank">@<span>InsertCaffeine</span></a></span> erklärt uns das Ganze genauer: <a href="https://www.laborjournal.de/editorials/3231.php" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">laborjournal.de/editorials/323</span><span class="invisible">1.php</span></a> <a href="https://mstdn.science/tags/Biotech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Biotech</span></a> <a href="https://mstdn.science/tags/CarTCells" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CarTCells</span></a> <a href="https://mstdn.science/tags/Antik%C3%B6rper" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Antikörper</span></a></p>